Study on evaluation of treatment and prognosis using Bon Scan Index (BSI) in the bone scintigraphy at the prostate cancer bone metastases evaluation

Study on evaluation of treatment and prognosis using Bon Scan Index (BSI) in the bone scintigraphy at the prostate cancer bone metastases evaluation - The evaluation of bone metastases using BSI in the bone scintigraphy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007858

Enrollment

300

Registered

2012-05-01

Start date

2012-04-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer with bone metastasis

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Prostate cancer with bone metastasis before hormonal therapy or Recurred prostate cancer with bone metastasis before docetaxel treatment

Exclusion criteria

Exclusion criteria: prostate cancer without bone metastasis

Design outcomes

Primary

Measure	Time frame
The correlation between rate of change PSA and the bone turnover markers and rate of change of the BSI by the treatment	—

Secondary

Measure	Time frame
The correlation between progression-free survival and overall survival and rate of change of the BSI by the treatment	—

Countries

Japan

Contacts

Public ContactAtsushi Mizokami

Kanazawa University Hospital Department of Urology

mizokami@staff.kanazawa-u.ac.jp076-265-2393

Outcome results